Definity

ALS

Sunnybrook Health Sciences CentrePhase 1Active

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 89/ 100

Competitive context

16 Active assets in the ALS cohort.

Asset / Sponsor	Phase	Rating
mt-1186 Tanabe Pharma Corporation	Phase 3	BB
Ceftriaxone Massachusetts General Hospital	Phase 3	B
Ciprofloxacin NeuroSense Therapeutics Ltd.	Phase 2	B
Talampanel Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2	B
Tocilizumab Barrow Neurological Institute	Phase 2	B

View all 27 →

Same molecule, other indications

Definity is also rated in:

Amyloidosis CardiacDormant

B

Indicative ·

62 / 100

Chemoembolization, TherapeuticDormant

B

Indicative ·

61 / 100

Hepatocellular CarcinomaDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.